Acelrx pharmaceuticals announces $10 million private placement of securities priced at-the-market under nasdaq rules

Upon the achievement of certain milestones accelerating the warrants' expiration date, acelrx may receive an additional $16.3 million of gross proceeds if the common warrants are exercised in full hayward, calif. , july 18, 2023 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), ("acelrx" or the "company"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 5,340,591 shares of common stock, at a purchase price of $1.36 per share of common stock, and pre-funded warrants to purchase 2,012,356 shares of common stock at a purchase price of $1.359 per pre-funded warrant (the "pre-funded warrants").
ACRX Ratings Summary
ACRX Quant Ranking